A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | NCT07221253

Overview

Key facts that identify this study and show where it stands today.

What the study is about and why it is being run, in the researchers' own words.

The medical conditions and diseases this study investigates.

The treatments and procedures being evaluated in this study.

Who can join this study and the criteria used to decide.

How the study is designed and how its participant groups are organized.

The people to reach with questions about this study or how to join it.

Where the study is run and whether each site is currently recruiting.

The organizations and people involved in this study.

Other registered studies that closely resemble this one.